B. Riley Wealth Advisors Inc. Has $906,000 Stake in Dr. Reddy's Laboratories Limited (NYSE:RDY)

B. Riley Wealth Advisors Inc. increased its stake in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 829.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 57,350 shares of the company's stock after purchasing an additional 51,180 shares during the quarter. B. Riley Wealth Advisors Inc.'s holdings in Dr. Reddy's Laboratories were worth $906,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Dr. Reddy's Laboratories by 100.2% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 16,511 shares of the company's stock valued at $261,000 after purchasing an additional 8,262 shares during the last quarter. Vident Advisory LLC grew its stake in shares of Dr. Reddy's Laboratories by 535.5% during the fourth quarter. Vident Advisory LLC now owns 151,331 shares of the company's stock valued at $2,390,000 after purchasing an additional 127,518 shares during the last quarter. Squarepoint Ops LLC bought a new stake in shares of Dr. Reddy's Laboratories during the fourth quarter valued at approximately $1,007,000. Two Sigma Advisers LP boosted its stake in Dr. Reddy's Laboratories by 254.8% in the fourth quarter. Two Sigma Advisers LP now owns 33,000 shares of the company's stock valued at $521,000 after acquiring an additional 23,700 shares during the last quarter. Finally, Thornburg Investment Management Inc. boosted its stake in Dr. Reddy's Laboratories by 232.3% in the fourth quarter. Thornburg Investment Management Inc. now owns 69,751 shares of the company's stock valued at $1,101,000 after acquiring an additional 48,763 shares during the last quarter. 3.85% of the stock is owned by institutional investors.

Dr. Reddy's Laboratories Trading Up 0.0%

RDY stock traded up $0.01 during midday trading on Monday, reaching $14.73. The company's stock had a trading volume of 1,166,380 shares, compared to its average volume of 1,482,965. Dr. Reddy's Laboratories Limited has a 52 week low of $12.26 and a 52 week high of $16.89. The stock has a market cap of $12.29 billion, a PE ratio of 23.45 and a beta of 0.33. The company has a quick ratio of 1.38, a current ratio of 1.92 and a debt-to-equity ratio of 0.02. The business's 50-day simple moving average is $13.71 and its 200-day simple moving average is $14.01.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last posted its earnings results on Friday, May 9th. The company reported $0.22 earnings per share for the quarter, topping the consensus estimate of $0.20 by $0.02. The company had revenue of $996.17 million for the quarter, compared to analyst estimates of $83.70 billion. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%. As a group, sell-side analysts expect that Dr. Reddy's Laboratories Limited will post 0.8 EPS for the current year.

Analysts Set New Price Targets

Separately, Wall Street Zen raised shares of Dr. Reddy's Laboratories from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th.

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.